VHL and neoplasm: Taken together with their ability to inhibit HIF-1/2α, we anticipate that these ISCA2 inhibitors will elicit potent anti-tumor activity by blocking the tumor enabling functions of HIF1/2α both within tumor cells and within components of the tumor-permissive microenvironment, while inducing ferroptotic death selectively within pVHL-deficient tumor cells.